References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailIntroduction: historical and current perspectives on osteoarthritis
Reginster, Jean-Yves ULg

in Arden, N; Blanco, F; Cooperr, C (Eds.) et al Atlas of Osteoarthritis (2014)

Detailed reference viewed: 6 (1 ULg)
See detailAtlas of osteoarthritis
Arden, N; Blanco, F; Cooper, C et al

Book published by Springer Verlag (2014)

This Atlas provides an up-to-date and comprehensive overview of the historical and current perspectives on osteoarthritis, including the pathophysiology and epidemiology of the disease. Written by leading ... [more ▼]

This Atlas provides an up-to-date and comprehensive overview of the historical and current perspectives on osteoarthritis, including the pathophysiology and epidemiology of the disease. Written by leading authors in the field of osteoarthritis, the book discusses classification, etiology and risk factors for osteoarthritis, the disease course and determinants of osteoarthritis progression, clinical features and diagnosis as well as imaging methods to assess joint damage. The Atlas of Osteoarthritis concludes with the latest treatment updates including both nonpharmacological and pharmacological treatments, as well as surgical recommendations for patients with the disease. Osteoarthritis is the most common form of joint disease causing joint pain, stiffness, and physical disability among adults. It is an important issue for both the individual and society with its impact on public health continuing to grow as a result of the aging population, the rising prevalence of obesity, and the lack of definitive treatments to prevent or halt the progress of the disease. [less ▲]

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailSarcopenia: burden and challenges for public health
Beaudart, Charlotte ULg; Rizzoli, R; Bruyère, Olivier ULg et al

in Archives of Public Health (2014), 72

Sarcopenia, operationally defined as the loss of muscle mass and muscle function, is a major health condition associated with ageing, and contributes to many components of public health at both the ... [more ▼]

Sarcopenia, operationally defined as the loss of muscle mass and muscle function, is a major health condition associated with ageing, and contributes to many components of public health at both the patient and the societal levels. Currently, no consensual definition of sarcopenia exists and therefore it is still a challenge to establish the actual prevalence of sarcopenia or to establish the direct and indirect impacts of sarcopenia on public health. Anyway, this geriatric syndrome represents a huge potential public health issue because of its multiple clinical and societal consequences. Moreover, all these aspects have an impact on healthcare costs both for the patient and the society. Therefore, the implementation of effective and broadly applicable preventive and therapeutic interventions has become a medical and societal challenge for the growing number of older persons affected by sarcopenia and its disabling complications. [less ▲]

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailPrevalence of sarcopenia: the impact of different diagnostic cut-off limits.
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Journal of musculoskeletal & neuronal interactions (2014), 14(4), 425-31

INTRODUCTION: In the definition of the European Working Group on Sarcopenia in Older People (EWGSOP), different cut-off limits are proposed for appendicular lean mass, muscle strength and gait speed ... [more ▼]

INTRODUCTION: In the definition of the European Working Group on Sarcopenia in Older People (EWGSOP), different cut-off limits are proposed for appendicular lean mass, muscle strength and gait speed. Therefore we aimed to examine the variation in prevalence of sarcopenia obtained with these cut-off limits. MATERIALS AND METHODS: Subjects aged 65 years and older were recruited in an outpatient clinic in Belgium and screened for sarcopenia using the EWGSOP definition. Appendicular lean mass was measured by Dual Energy X-Ray Absorptiometry, muscle strength by a hydraulic handgrip dynamometer and gait speed was measured on a 4-meter distance. Two different cut-off points proposed by the EWGSOP were examined for each variable and 8 diagnostic methods were thereby established. RESULTS: 400 subjects were recruited for this study. Prevalence of sarcopenia varied from 9.25% to 18% depending on the cut-offs applied. When stratified by sex, it seems that the variation in prevalence of sarcopenia was mainly attributable to women. This prevalence ranged from 6.58% to 20.2% for women and only from 13.4% to 14.7% for men. CONCLUSION: Prevalence of sarcopenia varies widely depending on the EWGSOP cut-off points applied for women. This may limit clinical researches and development of therapeutic strategies in the field of sarcopenia. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailA reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Hiligsmann, Mickaël ULg; Cooper, Cyrus; Guillemin, Francis et al

in Seminars in arthritis and rheumatism (2014), 44

BACKGROUND: General recommendations for a reference case for economic studies in rheumatic diseases were published in 2002 in an initiative to improve the comparability of cost-effectiveness studies in ... [more ▼]

BACKGROUND: General recommendations for a reference case for economic studies in rheumatic diseases were published in 2002 in an initiative to improve the comparability of cost-effectiveness studies in the field. Since then, economic evaluations in osteoarthritis (OA) continue to show considerable heterogeneity in methodological approach. OBJECTIVES: To develop a reference case specific for economic studies in OA, including the standard optimal care, with which to judge new pharmacologic and non-pharmacologic interventions. METHODS: Four subgroups of an ESCEO expert working group on economic assessments (13 experts representing diverse aspects of clinical research and/or economic evaluations) were charged with producing lists of recommendations that would potentially improve the comparability of economic analyses in OA: outcome measures, comparators, costs and methodology. These proposals were discussed and refined during a face-to-face meeting in 2013. They are presented here in the format of the recommendations of the recently published Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, so that an initiative on economic analysis methodology might be consolidated with an initiative on reporting standards. RESULTS: Overall, three distinct reference cases are proposed, one for each hand, knee and hip OA; with diagnostic variations in the first two, giving rise to different treatment options: interphalangeal or thumb-based disease for hand OA and the presence or absence of joint malalignment for knee OA. A set of management strategies is proposed, which should be further evaluated to help establish a consensus on the "standard optimal care" in each proposed reference case. The recommendations on outcome measures, cost itemisation and methodological approaches are also provided. CONCLUSIONS: The ESCEO group proposes a set of disease-specific recommendations on the conduct and reporting of economic evaluations in OA that could help the standardisation and comparability of studies that evaluate therapeutic strategies of OA in terms of costs and effectiveness. [less ▲]

Detailed reference viewed: 44 (26 ULg)
Full Text
Peer Reviewed
See detailAn algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Bruyère, Olivier ULg; Cooper, C; Pelletier, JP et al

in Seminars in Arthritis & Rheumatism (2014), 44

Objectives: Existing practice guidelines for osteoarthritis (OA) analyze the evidence behind each proposed treatment but do not prioritize the interventions in a given sequence. The objective was to ... [more ▼]

Objectives: Existing practice guidelines for osteoarthritis (OA) analyze the evidence behind each proposed treatment but do not prioritize the interventions in a given sequence. The objective was to develop a treatment algorithm recommendation that is easier to interpret for the prescribing physician based on the available evidence and that is applicable in Europe and internationally. The knee was used as the model OA joint. Methods: ESCEO assembled a task force of 13 international experts (rheumatologists, clinical epidemiologists, and clinical scientists). Existing guidelines were reviewed; all interventions listed and recent evidence were retrieved using established databases. A first schematic flow chart with treatment prioritization was discussed in a 1-day meeting and shaped to the treatment algorithm. Fine-tuning occurred by electronic communication and three consultation rounds until consensus. Results: Basic principles consist of the need for a combined pharmacological and non-pharmacological treatment with a core set of initial measures, including information access/education, weight loss if overweight, and an appropriate exercise program. Four multimodal steps are then established. Step 1 consists of background therapy, either non-pharmacological (referral to a physical therapist for re-alignment treatment if needed and sequential introduction of further physical interventions initially and at any time thereafter) or pharmacological. The latter consists of chronic Symptomatic Slow-Acting Drugs for OA (e.g., prescription glucosamine sulfate and/or chondroitin sulfate) with paracetamol at-need; topical NSAIDs are added in the still symptomatic patient. Step 2 consists of the advanced pharmacological management in the persistent symptomatic patient and is centered on the use of oral COX-2 selective or non-selective NSAIDs, chosen based on concomitant risk factors, with intra-articular corticosteroids or hyaluronate for further symptom relief if insufficient. In Step 3, the last pharmacological attempts before surgery are represented by weak opioids and other central analgesics. Finally, Step 4 consists of end-stage disease management and surgery, with classical opioids as a difficult-to-manage alternative when surgery is contraindicated. Conclusions: The proposed treatment algorithm may represent a new framework for the development of future guidelines for the management of OA, more easily accessible to physicians. © 2014 The Authors. [less ▲]

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailEstimation of sarcopenia prevalence using various assessment tools
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Experimental Gerontology (2014), 61

BACKGROUND: Sarcopenia is defined as a progressive and generalized loss of muscle mass with either a loss of muscle strength or a loss of physical performance but there is no recommendation regarding the ... [more ▼]

BACKGROUND: Sarcopenia is defined as a progressive and generalized loss of muscle mass with either a loss of muscle strength or a loss of physical performance but there is no recommendation regarding the diagnostic tools that have to be used. In this study, we compared the prevalence of sarcopenia assessed using different diagnostic tools. METHODS: To measure muscle mass, muscle strength and physical performance, we used for each outcome two different diagnostic tools. For muscle mass, we used Dual Energy X-Ray Absorptiometry (DXA) and bio-electrical impedance analysis (BIA); for muscle strength, we used a hydraulic dynamometer and a pneumatic dynamometer; for physical performance we used the Short Physical Performance Battery test (SPPB test) and the walk speed. Eight diagnostic groups were hereby established. RESULTS: A total of 250 consecutive subjects were recruited in an outpatient clinic in Liège, Belgium. Estimated prevalence of sarcopenia varied from 8.4% to 27.6% depending on the method of diagnosis used. Regarding muscle mass, BIA systematically overestimated muscle mass compared to DXA (mean estimated prevalence with BIA=12.8%; mean prevalence with DXA=21%). For muscle strength, the pneumatic dynamometer diagnosed twice more sarcopenic subjects than the hydraulic dynamometer (mean estimated prevalence with PD=22.4%; mean estimated prevalence with HD=11.4%). Finally, no difference in prevalence was observed when the walking speed or the SPPB test was used. A weak overall kappa coefficient was observed (0.53), suggesting that the 8 methods of diagnosis are moderately concordant. CONCLUSION: Within the same definition of sarcopenia, prevalence of sarcopenia is highly dependent on the diagnostic tools used. [less ▲]

Detailed reference viewed: 26 (13 ULg)
Full Text
Peer Reviewed
See detailAssociation entre la masse musculaire totale et la densité minérale osseuse de la hanche
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Cahiers de l'Année Gérontologique (Les) (2014), 2(23), 513-74

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailPrévalence de la sarcopénie : impact de l'utilisation de différentes valeurs seuils de diagnostic
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Cahiers de l'Année Gérontologique (Les) (2014), 2(23), 513-75

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailValidation des paramètres de marche par un système accélérométrique (Locométrix) à l’aide d’un système opto-électronique 3D (Coda Motion)
GILLAIN, Sophie ULg; Schwartz, C; Dramé, M et al

in Cahiers de l'Année Gérontologique (Les) (2014), 2(23), 724-73

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailEvaluation du nombre de résidents en maison de retraite médicalisée bénéficiant d'une supplémentation en vitamine D
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Cavalier, Etienne ULg et al

in Cahiers de l'Année Gérontologique (Les) (2014), 2(23), 207-63

Detailed reference viewed: 22 (9 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose demeure une maladie fatale : la vigilance reste de mise
Reginster, Jean-Yves ULg

in Medicographia (2014), 36(2), 141-142

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailDon't drop the guard: osteoporosis is still a fatal disease !
Reginster, Jean-Yves ULg

in Medicographia (2014), 36(2), 139-140

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of currently marketed anti-osteoporosis medications
Reginster, Jean-Yves ULg; NEUPREZ, Audrey ULg; Dardenne, Nadia ULg et al

in Best Practice & Research. Clinical Endocrinology & Metabolism (2014), 28

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally ... [more ▼]

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine anti-fracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications. [less ▲]

Detailed reference viewed: 42 (14 ULg)
Full Text
Peer Reviewed
See detailGaucher Disease and Bone Manifestations
Marcucci, Gemma; Zimran, Ari; Bembi, Bruno et al

in Calcified tissue international (2014), 95(6), 477-494

Gaucher disease is a relatively rare metabolic disease caused by the inherited deficiency of the lysosomal enzyme glucocerebrosidase. Gaucher disease affects multiple organs, among which is the skeleton ... [more ▼]

Gaucher disease is a relatively rare metabolic disease caused by the inherited deficiency of the lysosomal enzyme glucocerebrosidase. Gaucher disease affects multiple organs, among which is the skeleton. Bone involvement occurs frequently in Gaucher disease, and is one of its most debilitating features, reducing the quality of life of patients. Bone status is an important consideration for treatment to ameliorate symptoms and reduce the risk of irreversible complications. We have conducted a systematic review of all the various aspects of Gaucher disease, focusing on different skeletal manifestations, pathophysiology of bone alterations, clinical symptoms, and current diagnostic and therapeutic approaches. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailThe effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials.
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Rabenda, Véronique ULg et al

in The Journal of clinical endocrinology and metabolism (2014), 99(11), 4336-4345

Context There is growing evidence that vitamin D plays a role on several tissues including skeletal muscle. Objective To summarize with a meta-analyse the effects of vitamin D supplementation on muscle ... [more ▼]

Context There is growing evidence that vitamin D plays a role on several tissues including skeletal muscle. Objective To summarize with a meta-analyse the effects of vitamin D supplementation on muscle function. Data sources A systematic research of randomized controlled trials, performed between 1966 and January 2014 has been conducted on Medline, Cochrane Database of Systematics Reviews, Cochrane Central Register of Controlled and completed by a manual review of the literature and congressional abstracts. Study selection All forms and doses of vitamin D supplementation, with or without calcium supplementation, compared with placebo or control were included. Out of the 225 potentially relevant articles, 30 randomized controlled trials involving 5615 individuals (mean age: 61.1 years) met the inclusion criteria. Data extraction Data were extracted by two independent reviewers. Data synthesis Results revealed a small but significant positive effect of vitamin D supplementation on global muscle strength with a standardized mean difference (SMD) of 0.17 (p=0.02). No significant effect was found on muscle mass (SMD 0.058; p=0.52) or muscle power (SMD 0.057; p=0.657). Results on muscle strength were significantly more important with people who presented a 25-hydroxyvitamin D level <30 nmol/L. Supplementation seems also more effective on people aged 65 years or older compared to younger subjects (SMD 0.25; 95% CI 0.01 to 0.48 versus SMD 0.03; 95% CI -0.08 to 0.14). Conclusions Vitamin D supplementation has a small positive impact on muscle strength but additional studies are needed to define optimal treatment modalities, including dose, mode of administration and duration. [less ▲]

Detailed reference viewed: 44 (19 ULg)
Full Text
Peer Reviewed
See detailPréface
Reginster, Jean-Yves ULg

in Best Practice & Research. Clinical Endocrinology & Metabolism (2014), 28

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailMonitoring of osteoporosis therapy
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Best Practice & Research. Clinical Endocrinology & Metabolism (2014), 28

Over the past two decades, major advances have been made in the number and range of agents available for the treatment of osteoporosis, all with proven anti-fracture efficacy. Unfortunately, compliance ... [more ▼]

Over the past two decades, major advances have been made in the number and range of agents available for the treatment of osteoporosis, all with proven anti-fracture efficacy. Unfortunately, compliance with these treatments is not optimal, and a number of patients could be considered as non-responders. Consequently, monitoring anti-osteoporotic therapy could be part of successful osteoporosis management. Currently, no formal well-accepted clinical practice guidelines are available for monitoring anti-osteoporosis therapies. Changes in bone mineral density and bone turnover markers, while on therapy, have potential value in monitoring treatment but their assessment and, consequently, their benefits could be limited by metrological and clinical issues. Moreover, their effectiveness is probably drug dependant. Recommendation for the standardisation of the methodology when analysing the potential relevance of tools for the monitoring of osteoporosis therapy is needed. [less ▲]

Detailed reference viewed: 24 (10 ULg)